These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 20843566)
1. Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses. Henein MY; Owen A Int J Cardiol; 2011 Nov; 153(1):31-5. PubMed ID: 20843566 [TBL] [Abstract][Full Text] [Related]
2. Effect of statin treatment on aortic valve and coronary artery calcification. Mohler ER; Wang H; Medenilla E; Scott C J Heart Valve Dis; 2007 Jul; 16(4):378-86. PubMed ID: 17702362 [TBL] [Abstract][Full Text] [Related]
3. Statins, low-density lipoprotein cholesterol, and risk of cancer. Alsheikh-Ali AA; Trikalinos TA; Kent DM; Karas RH J Am Coll Cardiol; 2008 Sep; 52(14):1141-7. PubMed ID: 18804740 [TBL] [Abstract][Full Text] [Related]
4. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691 [TBL] [Abstract][Full Text] [Related]
5. Effect of lipid modification on progression of coronary calcification. McCullough PA J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S115-9. PubMed ID: 16251246 [TBL] [Abstract][Full Text] [Related]
6. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Raggi P; Davidson M; Callister TQ; Welty FK; Bachmann GA; Hecht H; Rumberger JA Circulation; 2005 Jul; 112(4):563-71. PubMed ID: 16009795 [TBL] [Abstract][Full Text] [Related]
7. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Wiviott SD; Cannon CP Curr Opin Lipidol; 2006 Dec; 17(6):626-30. PubMed ID: 17095906 [TBL] [Abstract][Full Text] [Related]
9. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Schmermund A; Achenbach S; Budde T; Buziashvili Y; Förster A; Friedrich G; Henein M; Kerkhoff G; Knollmann F; Kukharchuk V; Lahiri A; Leischik R; Moshage W; Schartl M; Siffert W; Steinhagen-Thiessen E; Sinitsyn V; Vogt A; Wiedeking B; Erbel R Circulation; 2006 Jan; 113(3):427-37. PubMed ID: 16415377 [TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. Robinson JG; Smith B; Maheshwari N; Schrott H J Am Coll Cardiol; 2005 Nov; 46(10):1855-62. PubMed ID: 16286171 [TBL] [Abstract][Full Text] [Related]
11. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E; J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of statin therapy in adults with coronary heart disease. Wilt TJ; Bloomfield HE; MacDonald R; Nelson D; Rutks I; Ho M; Larsen G; McCall A; Pineros S; Sales A Arch Intern Med; 2004 Jul; 164(13):1427-36. PubMed ID: 15249352 [TBL] [Abstract][Full Text] [Related]
13. Coronary event secondary prevention with statins irrespective of LDL-cholesterol. Kerst LL; Mauro VF Ann Pharmacother; 2004 Jun; 38(6):1060-4. PubMed ID: 15121997 [TBL] [Abstract][Full Text] [Related]
15. [Can statins slow the process of vascular calcification? Possibilities of lipid-lowering therapy and pleiotropic effect by statin treatment]. Iijima K; Ouchi Y Clin Calcium; 2010 Nov; 20(11):1719-28. PubMed ID: 21037393 [TBL] [Abstract][Full Text] [Related]
16. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol. Tani S; Nagao K; Hirayama A Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320 [TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Pedersen TR Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729 [TBL] [Abstract][Full Text] [Related]
18. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Bays HE; Davidson M; Jones MR; Abby SL Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026 [TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. Kinlay S J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355 [TBL] [Abstract][Full Text] [Related]
20. A comparison of HDL and LDL cholesterol for prevalent coronary calcification. Allison MA; Wright CM Int J Cardiol; 2004 May; 95(1):55-60. PubMed ID: 15159039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]